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model resources use. A reliable clinical and primary cost-
effectiveness study is warranted to take into account Canadian
publicly-funded health care system.
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OBJECTIVE: Epilepsy represents a national health problem. In
Mexico there are between 1.2 and 2.2 million diagnosed patients
who raise the demand for health care services. The aim of this
study was to analyze which antiepileptic drug is a cost-effective
therapy as an adjuvant treatment for the management of refrac-
tory partial seizures using a health care payer’s perspective.
\METHODS: A three-stage Markov model was used with a
follow-up period of one-year (4 cycles). Effectiveness measures
were the percentage of patients under control (no seizures) and
the number of hospitalizations avoided. The transition probabili-
ties were obtained from national and international published
literature. Comparators used in the assessment were topira-
mate (300–800 mg/day), levetiracetam (2000–3000 mg/day),
gabapentin (1200–1800 mg/day), lamotrigine (75–400 mg/day),
vigabatrin (1000–3000 mg/day) and pregabalin (150–600 mg/
day). Estimation of resource use was performed employing
hospital records from hospitals of the Social Security Mexican
Institute (IMSS). They include days of hospitalization, emer-
gency, outpatient services and drugs costs. The model was cali-
brated and probabilistic sensitivity analyses were conducted
using bootstrapping techniques. RESULTS: The highest rate of
controlled-patients was for pregabalin (54.1%;CI95% 53.3%–
55.1%) followed by topiramate (42.2%;CI95%41.5%–43.1%);
levetiracetam (34.1%;CI95% 33.4%–34.8%); vigabatrin
(32.6%;CI95% 32.0%–33.4%); gabapentin (27.4%;CI95%
26.9%–28.1%) and lamotrigine (24.7%;CI95% 24.1%–
25.3%). The annual expected mean cost per patient resulted
in US$3136.4 (CI95% US$3076.2–US$3139.8) for pregabalin;
US$4295.9 (CI95% US$4269.8–US$4318.3) for topiramate;
US$4037.7 (CI95% US$4015.6–US$4059.8) for levetirace-
tam; US$3470.9 (CI95% US$3450.1–US$3493.3) for
vigabatrin; US$3581.6 (CI95% US$3,552.3–US$3615.8) for
gabapentin; and US$2807.2 (CI95% US$2789.1–US$2825.4)
for lamotrigine. The ICER’s of the alternatives choosing
gabapentin as the gold standard were -US$1,769 (CI95%,
-US$1,685.3–US$1,812.8) for pregabalin, US$4,826.5 (CI95%
US$4,143.7–US$4,895.8) for topiramate; US$6,807.9 (CI95%
US$5,821.4–US$6986.7) for levetiracetam; -US$2,127.9
(CI95% -US$2,381.8,-US$1,561.2) for vigabatrin and
US$28,681.6 (CI95% US$28,569.1–US$49,547.0) for lamot-
rigine. Acceptability curves and component analyses showed that
these results remain robust. CONCLUSION: Pregabalin demon-
strated to be a cost-saving and cost-effectiveness adjuvant
therapy in the management of refractory partial seizures in
Mexican patients.
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OBJECTIVE: Natalizumab is a new disease modifying therapy
currently licensed for use in patients with relapsing-remitting
multiple sclerosis (RRMS), and has recently been the subject of a
cost-effectiveness evaluation by the National Institute for Health
and Clinical Excellence (NICE) in the UK. NICE accepted that
natalizumab was cost-effective in a highly-active subgroup of
RRMS patients, but not in all patients failing on current therapy
(sub-optimal therapy, SOT patients). In the SOT patients, the
basecase ICERs exceeded £43,400 and NICE essentially con-
cluded that natalizumab would not be a cost-effective use of NHS
resources in these patients unless they were having two or more
relapses per year. However, NICE recognised that the evaluation
may have underestimated the incremental QALY in two areas.
The ﬁrst was that the relapse disutility was underestimated, and
the second was that the time horizon of the evaluation was too
short. Here we re-evaluated the ICERs for natalizumab vs.
interferon-beta and glatiramer acetate in SOT patients taking
into account the points raised by NICE. METHODS: The origi-
nal model submitted to NICE was a 20-year markov-model
parameterised for the UK from a direct health care perspective.
Disutilities for relapse were updated using values from a previous
UK Health Technology Assessment, and the cost of relapse was
changed in line with contemporary studies. The time-horizon for
the model was extended from 20 years to 30 years. RESULTS:
The ICER from a direct medical costs perspective for natali-
zumab vs. interferon-beta was £29,900 per QALY. For natali-
zumab vs. glatiramer acetate the ICER was £29,300 per QALY.
CONCLUSION: The European Medicines Evaluation Agency
has approved natalizumab for use in highly active RRMS, includ-
ing SOT patients. Given the willingness-to-pay threshold of
£30,000 per QALY commonly associated with NICE guidance,
the results here show that natalizumab is a cost-effective treat-
ment for all patients failing on current therapy in the UK.
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OBJECTIVE: To determine the incremental cost-utility ratio
(ICUR) of Sativex®, a novel, cannabis-based therapy, as ad-
junctive treatment for neuropathic pain in MS adults from a
Canadian provincial government payer perspective over a one-
year time horizon. METHODS: Efﬁcacy and safety of Sativex®
were extracted from the pivotal phase III trial comparing
Sativex®+standard analgesic care (SAC) to SAC alone. Direct
medical resources (medication, health professionals, lab and
diagnostic) were taken from a burden of illness study. Sativex®
utilization for the economic analysis was based on the utilization
in the pivotal study (# sprays per day). Costs (2006 CND$) were
based on provincial sources. Utilities were based on a mapping
exercise whereby pain severity (BS-11) from the pivotal trial was
mapped onto Health Utilities Index Mark 3 (HUI) pain attribute
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level. The primary outcome was the cost per additional quality
adjusted life year (QALY). The incremental cost per additional
pain-controlled day was a secondary economic outcome. Sensi-
tivity analyses were conducted to investigate the robustness of
the results. RESULTS: The total direct cost of treatment over
one-year was $12,691 for Sativex® + SAC and $3,340 for SAC.
The total QALYs for Sativex® + SAC were 0.3793 and 0.2459
for SAC. The ICUR for Sativex® + SAC compared to SAC was
$70,103/QALY. The number of pain controlled days over
a one-year time horizon was 196 for Sativex® + SAC and
122 for SAC. Cost drivers were Sativex® utilization (5
daily sprays = $36,512/QALY; 11 sprays = $80,327/QALY). The
incremental cost per pain-controlled day was $127. CONCLU-
SION: Results indicated that Sativex® + SAC was more expen-
sive than SAC, but provided increased QALYs and pain-control
in MS patients with neuropathic pain.
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OBJECTIVE: To estimate the cost-utility of interferon beta-1b
(IFNB-1b) in the treatment of patients with a clinically isolated
syndrome (CIS) suggestive of multiple sclerosis (MS).
METHODS: We developed a Markov model of the epidemiol-
ogy and treatment of CIS and MS. The model allows users to
simulate outcomes over varying time horizons. A hypothetical
cohort of 1000 patients with incident CIS was speciﬁed, with
initial health states deﬁned by Kurtzke Expanded Disability
Symptom Scale (EDSS). The cohort was assumed alternatively to
be treated with IFNB-1b (250mg eod) following an initial demy-
elinating event suggestive of MS or not treated until conﬁrma-
tion of MS. Data from a published clinical study (BENEFIT)
were used to model EDSS progression over time and transitions
from CIS to MS. Relapses were estimated from BENEFIT and
published natural history data. Following transition to MS, all
patients were assumed to be treated with IFNB-1b until EDSS
6.5. Direct and indirect costs of MS treatment and IFNB-1b
were estimated from published literature and pricing schedules.
Patient utilities were derived from EQ-5D data from BENEFIT,
supplemented by published data deﬁned by EDSS score and
relapse occurrence. Mortality was estimated using life tables
and EDSS data. Costs (2007 currency) and outcomes were dis-
counted at 5% per annum. Sensitivity analyses were performed
on key model parameters. RESULTS: Use of IFNB-1b was asso-
ciated with slower EDSS progression (hence, longer time to MS
diagnosis), and reduced relapse burden. In the base case (Aus-
tralian perspective; 25-year simulation), incremental cost-utility
of IFNB-1b versus no treatment was AUD58,600 (USD$51,400)
per quality-adjusted life year (QALY) gained. Findings were sen-
sitive to years simulated, IFNB-1b cost and treatment effect,
and underlying rate of disease progression. CONCLUSION:
IFNB-1b treatment of patients with CIS apparently offers rea-
sonable value for money relative to many well-accepted health
care interventions.
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OBJECTIVE: Health care expenditures in Medicare are highly
concentrated in a small proportion of beneﬁciaries. The purpose
of this study was to quantify the concentration and persistence of
overall and prescription drug expenditures in individuals with
Alzheimer’s disease (AD) and to determine the characteristics
associated with future expenditure levels. METHODS: Data
were obtained from the 1999–2004 Medicare Current Beneﬁ-
ciary Survey linked with Medicare claims. Elderly, community-
dwelling individuals with AD were rank-ordered by overall and
drug expenditures. The proportion of expenditures accounted for
by the top 10%, top 25% and top 50% of spenders was calcu-
lated. A transition probability matrix was used to illustrate the
change in expenditure percentiles from one year to the next.
Ordered logit models incorporating prior expenditure, Charlson
Comorbidity Index, functional status and other background
covariates were performed to predict the level of subsequent-year
expenditures. RESULTS: The top 10% of spenders accounted for
38%–47% of overall health expenditures and incurred 31%–
36% of overall drug expenditures depending on the year.
One-quarter of the highest-spending 10% for total health expen-
ditures remained in the top decile in the next year, whereas 21%
of them moved to the bottom half in the subsequent year. Half of
the highest 10% of drug spenders retained this rank-
ing and 9% moved to the bottom 50% in the next year.
Prior expenditures and Charlson comorbidity scores, but not
functional status, were strong predictors of the level of future
expenditures. CONCLUSION: Overall health care and drug
expenditures were highly concentrated and persistent over a two-
year period in this AD population. Prescription drug expendi-
tures exhibited less concentration but more persistence than did
overall health expenditures. Results from this study may further
our knowledge of how expected high expenditures in AD
patients may be reduced with improved care coordination and
effective case management.
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Retrospective claims databases often lack disease severity mea-
sures. As a proxy for illness severity, a quintile analysis of
employees with multiple sclerosis (MS) was conducted. A
2001–2007 U.S. health care claims database was used to iden-
tify employees with MS (ICD-9 code=340.XX). Subjects were
followed for 1 year after their index dates, based on the ﬁrst
disease-modifying therapy (DMT) prescription (IFNâ-1a [SC or
IM], IFNâ-1b, or glatiramer acetate) or for those with no
therapy, the average date of those treated. MS-speciﬁc medical
costs were deﬁned as total claims costs with primary ICD-
9=340.XX. MS-speciﬁc drug costs were deﬁned as all DMT
expenditures. Employees were rank ordered by MS-speciﬁc
(medical and drug) costs and assigned to cost quintiles. In total,
765 employees with MS were analyzed, and 71.9% (n = 550)
with lowest cost (Quintile 1) incurred $1593 in MS-speciﬁc
(medical and drug) costs/employee. Quintiles 2–4 (8.9%, 8.0%,
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